|A living WHO guideline on drugs for covid-19|
A Agarwal, B Rochwerg, F Lamontagne, RAC Siemieniuk, T Agoritsas, ...
bmj 370, 2020
|Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study|
S Rodríguez-Nóvoa, P Labarga, V Soriano, D Egan, M Albalater, ...
Clinical Infectious Diseases 48 (11), e108-e116, 2009
|Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy|
A Lister, T Nedjadi, NR Kitteringham, F Campbell, E Costello, B Lloyd, ...
Molecular cancer 10 (1), 1-13, 2011
|HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms|
RC Hartkoorn, W San Kwan, V Shallcross, A Chaikan, N Liptrott, D Egan, ...
Pharmacogenetics and genomics 20 (2), 112, 2010
|Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients|
C Wyen, H Hendra, M Vogel, C Hoffmann, H Knechten, NH Brockmeyer, ...
Journal of antimicrobial chemotherapy 61 (4), 914-918, 2008
|Carbamazepine is not a substrate for P‐glycoprotein|
A Owen, M Pirmohamed, JN Tettey, P Morgan, D Chadwick, BK Park
British journal of clinical pharmacology 51 (4), 345-349, 2001
|Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy|
T Doyle, C Smith, P Vitiello, V Cambiano, M Johnson, A Owen, AN Phillips, ...
Clinical Infectious Diseases 54 (5), 724-732, 2012
|Research capacity. Enabling the genomic revolution in Africa|
C Rotimi, A Abayomi, A Abimiku, VM Adabayeri, C Adebamowo, ...
|Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein|
RC Hartkoorn, B Chandler, A Owen, SA Ward, SB Squire, DJ Back, ...
Tuberculosis 87 (3), 248-255, 2007
|The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications|
E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ...
Antimicrobial agents and chemotherapy 55 (9), 4122-4127, 2011
|On the issue of transparency and reproducibility in nanomedicine|
HS Leong, KS Butler, CJ Brinker, M Azzawi, S Conlan, C Dufès, A Owen, ...
Nature nanotechnology 14 (7), 629-635, 2019
|Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics|
U Arshad, H Pertinez, H Box, L Tatham, RKR Rajoli, P Curley, M Neary, ...
Clinical Pharmacology & Therapeutics 108 (4), 775-790, 2020
|Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine|
B Williamson, KE Dooley, Y Zhang, DJ Back, A Owen
Antimicrobial agents and chemotherapy 57 (12), 6366-6369, 2013
|Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing …|
C Wyen, H Hendra, M Siccardi, M Platten, H Jaeger, T Harrer, S Esser, ...
Journal of antimicrobial chemotherapy 66 (9), 2092-2098, 2011
|Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human …|
O Janneh, E Jones, B Chandler, A Owen, SH Khoo
Journal of antimicrobial chemotherapy 60 (5), 987-993, 2007
|Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction|
SP Pushpakom, NJ Liptrott, S Rodríguez-Nóvoa, P Labarga, V Soriano, ...
Journal of Infectious Diseases 204 (1), 145-153, 2011
|Transport of gabapentin by LAT1 (SLC7A5)|
D Dickens, SD Webb, S Antonyuk, A Giannoudis, A Owen, S Rädisch, ...
Biochemical pharmacology 85 (11), 1672-1683, 2013
|Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy|
A Owen, S Rannard
Advanced drug delivery reviews 103, 144-156, 2016
|The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro|
B Chandler, L Almond, J Ford, A Owen, P Hoggard, S Khoo, D Back
JAIDS Journal of Acquired Immune Deficiency Syndromes 33 (5), 551-556, 2003
|Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex|
GA Biagini, N Fisher, N Berry, PA Stocks, B Meunier, DP Williams, ...
Molecular Pharmacology 73 (5), 1347-1355, 2008